Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, H…
Drug Manufacturers - General
US, Indianapolis [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 43.68 | 1.35 | 0.94 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 18.97 | 7.40 | 6.22 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 25.36 | 14.22 | 11.35 | |
| Cash | -6.90 | 2.87 | 3.08 | |
| Capex | 37.04 | -1.09 | -1.74 | |
| Free Cash Flow | -90.35 | 0.20 | -2.07 | |
| Revenue | -1.20 | 9.73 | 9.85 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.29 | 0.83 | 0.82 | |
| Operating Margin | -9.22 | 0.30 | 0.33 | |
| ROA | 2.53 | 0.04 | 0.03 | |
| ROE | -13.88 | 0.18 | 0.20 | |
| ROIC | -20.45 | 0.06 | 0.07 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of LLY is permitted for members.
5
Growth
The "Growth Entry" for the Focus of LLY is permitted for members.
6
Leverage & Liquidity